Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.

[1]  D. Mikhailidis,et al.  Do statins have an antiarrhythmic activity? , 2007, Cardiovascular research.

[2]  Panagiotis Korantzopoulos,et al.  Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. , 2007, Journal of the American College of Cardiology.

[3]  W. Howard.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[4]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study , 2006, Circulation.

[5]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[6]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[7]  E. Varol,et al.  Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. , 2006, The American journal of cardiology.

[8]  Guangping Li,et al.  Statins may prevent postoperative atrial fibrillation through autonomic modulation. , 2006, The American journal of cardiology.

[9]  F. Agrò,et al.  Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery , 2006, Critical care medicine.

[10]  J. Dernellis,et al.  Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. , 2005, American heart journal.

[11]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[12]  J. McMurray,et al.  A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.

[13]  J. Svendsen,et al.  Inflammation in the genesis and perpetuation of atrial fibrillation. , 2005, European heart journal.

[14]  G. Lamas,et al.  Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy , 2005 .

[15]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[16]  J. Mathew,et al.  A multicenter risk index for atrial fibrillation after cardiac surgery. , 2004, JAMA.

[17]  A. Tveit,et al.  Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. , 2004, The American journal of cardiology.

[18]  R. Rosenson.  Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. , 2004, Atherosclerosis.

[19]  P. Libby,et al.  High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study , 2003, Circulation.

[20]  M. Luzi,et al.  Atrial fibrillation: the remodelling phenomenon , 2003 .

[21]  Kathleen M. Weil,et al.  Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction , 2002, Circulation.

[22]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[23]  I. Olkin,et al.  Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement , 2000, Revista espanola de salud publica.

[24]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[25]  T. Strandberg,et al.  Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.

[26]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[27]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[28]  F. Mosteller,et al.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.

[29]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[30]  H. Toutenburg.  Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .

[31]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[32]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.